In this section, you will find new information and key facts on various aspects of Canada’s research-based pharmaceutical industry.
One of the most rigorous and detailed forecasts ever conducted for the Canadian private drug plan market shows that drug cost growth within private plans will be in the low single digit range in the coming 5-year period. This news is important for Canadian employers who offer drug coverage to their employees as part of their health benefit plans. These results show that, at a market level, the private drug plan system growth will be sustainable.
Rx&D commissioned IMS Brogan, the Canadian business unit of IMS Health a global leader in healthcare market insights, to conduct a forecast of private drug plan drug costs for 2013-2017. The IMS Brogan Private Drug Plan Drug Forecast shows that the Compounded Annual Growth Rate (CAGR) of private market drug costs, at an overall market level, will be in the range of 1.6% to 2.8 % over the five-year forecast period.
This is the sixth edition of IRAM, an annual study published by Canada’s Research-Based Pharmaceutical Companies (Rx&D). IRAM’s priority objective is to explore how the public reimbursement of innovative medicines in Canada compares to that found in other member countries of the Organization for Economic Cooperation and Development (OECD ).
The study produces a ranking of OECD nations that compares how well Canadian public drug plans reimburse various drug and certain disease categories versus the average of the rest of the OECD nations. This edition reviews 204 drugs representing 257 indications, the most ever reported, and covers 32 countries in the OECD .
Summary of 2012 R&D Spending and Investments by Rx&D Members
For the third consecutive year, a KPMG study commissioned by Canada’s Research-Based Pharmaceutical Companies (Rx&D) has determined that research and development (R&D) investments made by Canada’s innovative pharmaceutical sector continue to be consistently underreported, by approximately 34 per cent for 2012. The report, entitled Summary of 2012 R&D Spending and Investments by Rx&D Members, is the result of information gathered by KPMG and presents a more fulsome picture of the industry’s investment than the reports issued in previous years by the Patented Medicine Prices Review Board (PMPRB). It is anticipated that the 2012 report of the PMPRB will show this same trend.